Hologic to acquire Sentinelle Medical for $85M

Lisa Fratt | | Health Imaging | Oncology Imaging
Breast MRI Navigation software
Image source: Sentinelle Medical
Hologic has entered into a definitive agreement to acquire Sentinelle Medical, a provider of MRI breast coils, tables and visualization software.

The purchase price for the transaction will be $85 million, plus a two-year contingent earn out. The earn out will be payable in cash installments equal to a multiple of the incremental revenue growth in Sentinelle’s business in the two years following the closing, according to the Bedford, Mass.-based Hologic.

Hologic predicted that the transaction will close during the third calendar quarter and is subject to customary closing conditions, including, among others, Sentinelle stockholder approval and Canadian judicial approval.

Sentinelle, a privately-held medical imaging company headquartered in Toronto, develops breast imaging technologies using high-field strength MRI. The developer is currently an industry partner with GE Healthcare, Siemens Healthcare and Toshiba America Medical Systems.

Sentinelle’s revenue in calendar 2009 was approximately $15 million. Hologic expects this acquisition to be neutral to earnings in fiscal 2011, absent the amortization of intangibles related to the transaction and other acquisition-related charges.

Lisa Fratt

Related Content

MRI-first approach could allow many to safely forego prostate biopsy
MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
Breast cancer only visible via MRI is often less aggressive

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.